# Evaluation of a New Critical Pathway for Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI)

> **NCT02961764** · PHASE4 · COMPLETED · sponsor: **Allergan** · enrollment: 313 (actual)

## Conditions studied

- Acute Bacterial Skin and Skin Structure Infections

## Interventions

- **DRUG:** Usual Care
- **DRUG:** Dalbavancin

## Key facts

- **NCT ID:** NCT02961764
- **Lead sponsor:** Allergan
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-11-29
- **Primary completion:** 2019-03-29
- **Final completion:** 2019-03-29
- **Target enrollment:** 313 (ACTUAL)
- **Last updated:** 2020-04-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02961764

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02961764, "Evaluation of a New Critical Pathway for Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI)". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT02961764. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*